ABOUT US
At GenesX, we empower the world’s leading research institutions and universities with advanced genomic technologies like FLAP&CAP. By combining precision, innovation, & usability, we provide tools that decode the complexities of DNA, enabling groundbreaking discoveries in health, science, and medicine.
OUR MISSION
Our mission is to revolutionize genomic research by equipping labs and institutions with cutting-edge solutions that transform ideas into innovation. We believe that understanding the language of DNA inspires progress, fueling breakthroughs that shape the future of science and humanity.
MEET OUR FOUNDER, MICHAEL KLADDE.
A TRUE PIONEER LAUNCHING EPIGENETICS
INTO THE NEXT FRONTIER. HE KNOWS HOW
TO TAKE THINGS TO THE NEXT LEVEL. JOIN US
AS WE BLAST OFF INTO A NEW ERA OF DISCOVERY.
Meet
Our Founder
GenesX Founder, Dr. Michael Kladde, earned his Ph.D. degree in Cellular and Molecular Biology at the University of Wisconsin-Madison in 1991. He completed his postdoctoral training in 1998 at the National Institutes of Health and the Pennsylvania State University, establishing his independent laboratory the same year at Texas A&M University. Dr. Kladde established his independent laboratory at Texas A&M University in 1998 and rose to the rank of Associate Professor. In 2007, he joined the Department of Biochemistry and Molecular Biology at the University of Florida. He was promoted to full Professor in 2013 and has served as the UF Director of the Center for Epigenetics since 2020.
Dr. Kladde’s research focus since 1986 has been the study of epigenetic regulation of gene expression, amassing 40 years of expertise in the field. He has an accomplished record of developing innovative technologies that have addressed and answered formerly intractable mysteries, resulting in groundbreaking scientific advances. Dr. Kladde devised the first strategy to detect long-range communication and interactions between gene regulatory sequences (Cullen, Kladde, and Seyfred, Science, 1993). Dr. Kladde also pioneered the use of DNA methyltransferases, patenting and licensing the first GpC DNA methyltransferase for single-molecule mapping of nucleosomes, DNA-bound transcription factors, and CpG methylation, a foundational technology of GenesX. Dr. Kladde and colleagues developed GenesX’s ‘X’ factor—technologies (issued and pending patents) for on-target sequence enrichment of specific DNA sequences from any cells for unparalleled, highly sensitive detection of clinically relevant epigenetic states and genetic mutations.
Dr. Michael Kladde
